• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雌激素受体α在细胞增殖和癌症中的新作用:激活预期性未折叠蛋白反应

A New Role for Estrogen Receptor α in Cell Proliferation and Cancer: Activating the Anticipatory Unfolded Protein Response.

作者信息

Livezey Mara, Kim Ji Eun, Shapiro David J

机构信息

Department of Biochemistry, University of Illinois, Urbana, IL, United States.

Center for Cancer Research, University of Illinois, Urbana, IL, United States.

出版信息

Front Endocrinol (Lausanne). 2018 Jun 15;9:325. doi: 10.3389/fendo.2018.00325. eCollection 2018.

DOI:10.3389/fendo.2018.00325
PMID:29963013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6013567/
Abstract

Cells react to a variety of stresses, including accumulation of unfolded or misfolded protein, by activating the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). The UPR is highly conserved and plays a key role in the maintenance of protein folding quality control and homeostasis. In contrast to the classical reactive mode of UPR activation, recent studies describe a hormone-activated anticipatory UPR. In this pathway, mitogenic hormones, such as estrogen (E), epidermal growth factor, and vascular endothelial growth factor rapidly activate the UPR in anticipation of a future need for increased protein folding capacity upon cell proliferation. Here, we focus on this recently unveiled pathway of E-estrogen receptor α (ERα) action. Notably, rapid activation of the anticipatory UPR pathway is essential for subsequent activation of the E-ERα regulated transcription program. Moreover, activation of the UPR at diagnosis is a powerful prognostic marker in ERα positive breast cancer. Furthermore, in cells containing ERα mutations that confer estrogen independence and are common in metastatic breast cancer, the UPR is constitutively activated and linked to antiestrogen resistance. Lethal ERα-dependent hyperactivation of the anticipatory UPR represents a promising therapeutic approach exploited by a new class of small molecule ERα biomodulator.

摘要

细胞通过激活内质网(EnR)应激传感器——未折叠蛋白反应(UPR),对包括未折叠或错误折叠蛋白积累在内的多种应激作出反应。UPR高度保守,在维持蛋白质折叠质量控制和内环境稳定方面发挥关键作用。与经典的UPR激活反应模式不同,最近的研究描述了一种激素激活的预期性UPR。在这条途径中,有丝分裂激素,如雌激素(E)、表皮生长因子和血管内皮生长因子,会在预期细胞增殖时对蛋白质折叠能力增加的未来需求时迅速激活UPR。在这里,我们关注这条最近才被揭示的E-雌激素受体α(ERα)作用途径。值得注意的是,预期性UPR途径的快速激活对于随后激活E-ERα调节的转录程序至关重要。此外,诊断时UPR的激活是ERα阳性乳腺癌的一个强大预后标志物。此外,在含有赋予雌激素独立性且在转移性乳腺癌中常见的ERα突变的细胞中,UPR被组成性激活并与抗雌激素耐药性相关。预期性UPR的致命性ERα依赖性过度激活代表了一种有前景的治疗方法,被一类新型小分子ERα生物调节剂所利用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d29/6013567/c03c5e32a7c6/fendo-09-00325-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d29/6013567/2009bef8054a/fendo-09-00325-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d29/6013567/c03c5e32a7c6/fendo-09-00325-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d29/6013567/2009bef8054a/fendo-09-00325-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d29/6013567/c03c5e32a7c6/fendo-09-00325-g002.jpg

相似文献

1
A New Role for Estrogen Receptor α in Cell Proliferation and Cancer: Activating the Anticipatory Unfolded Protein Response.雌激素受体α在细胞增殖和癌症中的新作用:激活预期性未折叠蛋白反应
Front Endocrinol (Lausanne). 2018 Jun 15;9:325. doi: 10.3389/fendo.2018.00325. eCollection 2018.
2
Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.未折叠蛋白反应的预期性雌激素激活与雌激素受体α阳性乳腺癌的细胞增殖及不良预后相关。
Oncogene. 2015 Jul;34(29):3760-9. doi: 10.1038/onc.2014.292. Epub 2014 Sep 29.
3
Interplay between steroid hormone activation of the unfolded protein response and nuclear receptor action.未折叠蛋白反应的类固醇激素激活与核受体作用之间的相互作用。
Steroids. 2016 Oct;114:2-6. doi: 10.1016/j.steroids.2016.03.014. Epub 2016 Mar 23.
4
Src couples estrogen receptor to the anticipatory unfolded protein response and regulates cancer cell fate under stress.Src 将雌激素受体与预期的未折叠蛋白反应偶联,并在应激下调节癌细胞命运。
Biochim Biophys Acta Mol Cell Res. 2020 Oct;1867(10):118765. doi: 10.1016/j.bbamcr.2020.118765. Epub 2020 Jun 2.
5
Strong and sustained activation of the anticipatory unfolded protein response induces necrotic cell death.强烈而持续的未折叠蛋白反应的激活会诱导细胞发生坏死性死亡。
Cell Death Differ. 2018 Oct;25(10):1796-1807. doi: 10.1038/s41418-018-0143-2. Epub 2018 Jun 13.
6
Anticipatory UPR Activation: A Protective Pathway and Target in Cancer.预期性未折叠蛋白反应激活:癌症中的一种保护途径及靶点
Trends Endocrinol Metab. 2016 Oct;27(10):731-741. doi: 10.1016/j.tem.2016.06.002. Epub 2016 Jun 25.
7
Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression.雌激素受体α抑制剂激活未折叠蛋白反应,阻断蛋白质合成,并诱导肿瘤消退。
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4737-42. doi: 10.1073/pnas.1403685112. Epub 2015 Mar 30.
8
Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer.雌激素受体与未折叠蛋白反应:在治疗雌激素受体阳性乳腺癌中的双刃剑。
Target Oncol. 2022 Mar;17(2):111-124. doi: 10.1007/s11523-022-00870-5. Epub 2022 Mar 15.
9
Estrogen receptor-α signaling and localization regulates autophagy and unfolded protein response activation in ER+ breast cancer.雌激素受体-α信号传导与定位调节雌激素受体阳性乳腺癌中的自噬及未折叠蛋白反应激活。
Receptors Clin Investig. 2014;1(6). doi: 10.14800/rci.316.
10
Anticipatory activation of the unfolded protein response by epidermal growth factor is required for immediate early gene expression and cell proliferation.表皮生长因子对未折叠蛋白反应的预期激活是立即早期基因表达和细胞增殖所必需的。
Mol Cell Endocrinol. 2016 Feb 15;422:31-41. doi: 10.1016/j.mce.2015.11.005. Epub 2015 Nov 6.

引用本文的文献

1
Modulating mitochondria with natural extract compounds: from bench to clinical therapeutic opportunities for COPD.用天然提取物化合物调节线粒体:从实验室到慢性阻塞性肺疾病的临床治疗机遇
Front Pharmacol. 2025 May 21;16:1531302. doi: 10.3389/fphar.2025.1531302. eCollection 2025.
2
A necrosis inducer promotes an immunogenic response and destroys ovarian cancers in mouse xenografts and patient ascites organoids.一种坏死诱导剂可促进免疫原性反应,并在小鼠异种移植瘤和患者腹水类器官中破坏卵巢癌。
Cancer Lett. 2025 Aug 10;625:217738. doi: 10.1016/j.canlet.2025.217738. Epub 2025 Apr 29.
3
Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer.

本文引用的文献

1
Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response.通过未折叠蛋白反应的过度激活导致雌激素受体α依赖性ATP耗竭来靶向多药耐药性卵巢癌。
Oncotarget. 2016 Jul 24;9(19):14741-14753. doi: 10.18632/oncotarget.10819. eCollection 2018 Mar 13.
2
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.靶向 MYC 调控的 IRE1/XBP1 通路抑制 MYC 驱动的乳腺癌。
J Clin Invest. 2018 Apr 2;128(4):1283-1299. doi: 10.1172/JCI95873. Epub 2018 Feb 26.
3
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.
全反式维甲酸联合他莫昔芬治疗卵巢癌。
Cancer Chemother Pharmacol. 2024 Aug;94(2):259-270. doi: 10.1007/s00280-024-04671-7. Epub 2024 May 7.
4
ERα promotes transcription by binding with the ERE and enhances SUMO1-mediated protein SUMOylation in breast cancer.雌激素受体α(ERα)通过与雌激素反应元件(ERE)结合促进转录,并增强乳腺癌中SUMO1介导的蛋白质SUMO化。
Gland Surg. 2023 Jul 31;12(7):963-973. doi: 10.21037/gs-23-39.
5
Insight into the Potential Mechanisms of Endocrine Disruption by Dietary Phytoestrogens in the Context of the Etiopathogenesis of Endometriosis.膳食植物雌激素在子宫内膜异位症发病机制中的内分泌干扰潜在机制的研究进展。
Int J Mol Sci. 2023 Jul 30;24(15):12195. doi: 10.3390/ijms241512195.
6
The mitochondrial unfolded protein response (UPR): shielding against toxicity to mitochondria in cancer.线粒体未折叠蛋白反应(UPR):在癌症中抵御线粒体毒性。
J Hematol Oncol. 2022 Jul 21;15(1):98. doi: 10.1186/s13045-022-01317-0.
7
Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity.3-(4-羟基苯基)吲哚啉-2-酮作为具有强效和选择性抗癌活性支架的演变。
RSC Med Chem. 2022 May 9;13(6):711-725. doi: 10.1039/d2md00110a. eCollection 2022 Jun 22.
8
TXNIP Links Anticipatory Unfolded Protein Response to Estrogen Reprogramming Glucose Metabolism in Breast Cancer Cells.TXNIP 将未折叠蛋白反应与雌激素重编程乳腺癌细胞的葡萄糖代谢联系起来。
Endocrinology. 2022 Jan 1;163(1). doi: 10.1210/endocr/bqab212.
9
Quality Matters? The Involvement of Mitochondrial Quality Control in Cardiovascular Disease.质量至关重要?线粒体质量控制在心血管疾病中的作用
Front Cell Dev Biol. 2021 Mar 22;9:636295. doi: 10.3389/fcell.2021.636295. eCollection 2021.
10
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.癌细胞中对小分子抑制剂的继发性耐药突变
Cancers (Basel). 2020 Apr 9;12(4):927. doi: 10.3390/cancers12040927.
结构新颖的抗雌激素对乳腺癌细胞和肿瘤中组成型活性突变雌激素受体产生不同反应。
Cancer Res. 2017 Oct 15;77(20):5602-5613. doi: 10.1158/0008-5472.CAN-17-1265. Epub 2017 Sep 13.
4
Endoplasmic Reticulum Stress and the Hallmarks of Cancer.内质网应激与癌症特征
Trends Cancer. 2016 May;2(5):252-262. doi: 10.1016/j.trecan.2016.03.007. Epub 2016 Apr 23.
5
Metabolic regulation of the PMCA: Role in cell death and survival.PMCA 的代谢调控:在细胞死亡和存活中的作用。
Cell Calcium. 2018 Jan;69:28-36. doi: 10.1016/j.ceca.2017.06.001. Epub 2017 Jun 8.
6
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER Breast Cancer Patient-derived Xenograft Models.拉曲替布(RAD1901),一种选择性雌激素受体降解剂(SERD),在多种 ER 阳性乳腺癌患者来源异种移植模型中具有抗肿瘤活性。
Clin Cancer Res. 2017 Aug 15;23(16):4793-4804. doi: 10.1158/1078-0432.CCR-16-2561. Epub 2017 May 4.
7
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.针对难治性乳腺癌研发的新型选择性雌激素受体下调剂(SERDs)
J Med Chem. 2017 Feb 23;60(4):1325-1342. doi: 10.1021/acs.jmedchem.6b01355. Epub 2017 Feb 10.
8
Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.表达雌激素受体 α 突变的抗雌激素耐药细胞系上调未折叠蛋白反应,并被 BHPI 杀死。
Sci Rep. 2016 Oct 7;6:34753. doi: 10.1038/srep34753.
9
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.循环肿瘤 DNA 中 ESR1 突变的流行率与转移性乳腺癌的结局:BOLERO-2 临床试验的二次分析。
JAMA Oncol. 2016 Oct 1;2(10):1310-1315. doi: 10.1001/jamaoncol.2016.1279.
10
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.接受氟维司群治疗的 ER 阳性转移性乳腺癌患者中 ESR1 突变的异质性和临床意义。
Nat Commun. 2016 May 13;7:11579. doi: 10.1038/ncomms11579.